Patents Assigned to NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING
  • SOLUBLE ACE2 AND FUSION PROTEIN, AND APPLICATIONS THEREOF
    Publication number: 20230348880
    Abstract: A soluble ACF and a truncated form thereof, a fusion protein thereof and preparation methods therefor. A soluble ACEI and a truncated form thereof, as well as a use of the fusion protein in the preparation of a drug for an ACEI-related disease.
    Type: Application
    Filed: February 27, 2021
    Publication date: November 2, 2023
    Applicant: National Institute of Biological Sciences, Beijing
    Inventors: Wenhui Li, Yonghe Qi, Jianhe Chen, Jianhua Sui, Juan Liu, Fengfeng Mao, Ximing Liu
  • Apoptosis inhibitors
    Patent number: 11725000
    Abstract: The invention provides compounds that are inhibitors or covalent modifiers of succinate dehydrogenase subunit B (SDHB) and/or inhibitors of apoptosis, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: August 15, 2023
    Assignee: National Institute of Biological Sciences, Beijing
    Inventors: Zhiyuan Zhang, Xiaodong Wang, Shaoqiang Huang, Xian Jiang, Li Li, Zhaolan Zhang, Jianguang Han
  • MLKL inhibitors
    Patent number: 11666577
    Abstract: The invention provides compounds that inhibit human MLKL, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: June 6, 2023
    Assignee: National Institute of Biological Sciences, Beijing
    Inventors: Zhiyuan Zhang, Xiaodong Wang, Shaoqiang Huang, Bo Yan, Lei Liu, Huayi Wang, Jianguang Han, Zhi Huang, Weiye Cao
  • Necrosis inhibitors
    Patent number: 11478438
    Abstract: The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: October 25, 2022
    Assignee: National Institute of Biological Sciences, Beijing
    Inventors: Zhiyuan Zhang, Xiaodong Wang, Yaning Su, Hanying Ruan, Yan Ren
  • PROSTHESIS FOR THE LUNG AND THE USE THEREOF
    Publication number: 20220273413
    Abstract: The invention relates to prosthesis for treating pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), and a method for treating pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF).
    Type: Application
    Filed: May 30, 2019
    Publication date: September 1, 2022
    Applicant: National Institute of Biological Sciences, Beijing
    Inventors: Nan Tang, Huijuan Wu, Jiao Li
  • ANIMAL MODEL OF IDIOPATHIC PULMONARY FIBROSIS, ITS CONSTRUCTION METHOD AND USE
    Publication number: 20220273822
    Abstract: The present invention relates to a method for constructing an animal model of pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF), the constructed animal model using the said method, and a method for screening the candidate drugs for treating pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF).
    Type: Application
    Filed: May 30, 2019
    Publication date: September 1, 2022
    Applicant: National Institute of Biological Sciences, Beijing
    Inventors: Nan Tang, Huijuan Wu
  • DRUG TARGET OF IDIOPATHIC PULMONARY FIBROSIS
    Publication number: 20220275055
    Abstract: Provided is a drug target for idiopathic pulmonary fibrosis, and the use thereof. The drug target is AREG signaling in AT2 cells of the lung. The drug target can be used to screen drugs for treating and/or preventing pulmonary fibrosis, in particular, idiopathic pulmonary fibrosis (IPF) of animals and human beings.
    Type: Application
    Filed: May 30, 2019
    Publication date: September 1, 2022
    Applicant: National Institute of Biological Sciences, Beijing
    Inventors: Nan Tang, Huijuan Wu
  • Apoptosis Inhibitors
    Publication number: 20210309647
    Abstract: The invention provides compounds that are inhibitors or covalent modifiers of succinate dehydrogenase subunit B (SDHB) and/or inhibitors of apoptosis, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition.
    Type: Application
    Filed: May 28, 2021
    Publication date: October 7, 2021
    Applicant: National Institute of Biological Sciences, Beijing
    Inventors: Zhiyuan Zhang, Xiaodong Wang, Shaoqiang Huang, Xian Jiang, Li Li, Zhaolan Zhang, Jianguang Han
  • Treating male senescence
    Patent number: 11090307
    Abstract: The invention provides methods of treating male reproductive senescence comprising administering to a male in need thereof a necroptosis inhibitor, including inhibitors of RIP1, RIP3 or MLKL. The invention also provides pharmaceutical compositions comprising a necroptosis inhibitor and a second different drug for treating male senescence.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: August 17, 2021
    Assignee: National Institute of Biological Sciences, Beijing
    Inventors: Xiaodong Wang, Dianrong Li, Lingjun Meng, Zhiyuan Zhang
  • FTO Inhibitors
    Publication number: 20210238127
    Abstract: The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
    Type: Application
    Filed: April 18, 2021
    Publication date: August 5, 2021
    Applicant: National Institute of Biological Sciences, Beijing
    Inventors: Niu Huang, Shiming Peng
  • Apoptosis inhibitors
    Patent number: 11034680
    Abstract: The invention provides compounds that are inhibitors or covalent modifiers of succinate dehydrogenase subunit B (SDHB) and/or inhibitors of apoptosis, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: June 15, 2021
    Assignee: National Institute of Biological Sciences, Beijing
    Inventors: Zhiyuan Zhang, Xiaodong Wang, Shaoqiang Huang, Xian Jiang, Li Li, Zhaolan Zhang, Jianguang Han
  • FTO inhibitors
    Patent number: 10988440
    Abstract: The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
    Type: Grant
    Filed: January 12, 2020
    Date of Patent: April 27, 2021
    Assignee: National Institute of Biological Sciences, Beijing
    Inventors: Niu Huang, Shiming Peng
  • Cathepsin C inhibitors
    Publication number: 20210114983
    Abstract: Disclosed compounds, pharmaceutical compositions are used for inhibiting cathepsin C without inhibiting epidermal growth factor receptor (EGFR).
    Type: Application
    Filed: December 30, 2020
    Publication date: April 22, 2021
    Applicant: National Institute of Biological Sciences, Beijing
    Inventors: Zhiyuan Zhang, Weijie Hou, Huan Sun
  • Entacapone-related compounds to treat macular degeneration
    Patent number: 10980766
    Abstract: The invention provides use of entacapone, an entacapone derivative or a stereoisomer, hydride, or pharmaceutically-acceptable salt thereof, in a person in need thereof, to treat or inhibit macular degeneration or age-related macular degeneration, and related compostions.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: April 20, 2021
    Assignee: National Institute of Biological Sciences, Beijing
    Inventors: Niu Huang, Shiming Peng
  • NTCP inhibitors
    Patent number: 10961231
    Abstract: The invention provides cyclosporin A analogues that are NTCP inhibitors and useful for treating HBV and/or HDV infection(s), hepatoprotection and amelioration of hypercholesterolemia, diabetes and inhibiting cancer.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: March 30, 2021
    Assignee: National Institute of Biological Sciences, Beijing
    Inventors: Zhiyuan Zhang, Wenhui Li, Hanying Ruan, Yang Liu, Fengfeng Mao, Ying Li, Zhongmin Zhou
  • NTCP Inhibitors
    Publication number: 20210040072
    Abstract: The invention provides cyclosporin A analogues that are NTCP inhibitors and useful for treating HBV and/or HDV infection(s), hepatoprotection and amelioration of hypercholesterolemia, diabetes and inhibiting cancer.
    Type: Application
    Filed: October 12, 2020
    Publication date: February 11, 2021
    Applicant: National Institute of Biological Sciences, Beijing
    Inventors: Zhiyuan Zhang, Wenhui Li, Hanying Ruan, Yang Liu, Fengfeng Mao, Ying Li, Zhongmin Zhou
  • Promoting Immune Responses
    Publication number: 20200405869
    Abstract: Pharmaceutical compositions comprise a 1-ADP-heptose conjugate and may include an immunogen or an immune checkpoint inhibitor, and are used to promote an immune response.
    Type: Application
    Filed: September 15, 2020
    Publication date: December 31, 2020
    Applicant: National Institute of Biological Sciences, Beijing
    Inventors: Feng Shao, Ping Zhou, Yang She, Huabin He, Peng Li, Jingjin Ding, Wenqing Gao
  • HYBRIDIZATION CHAIN REACTION-BASED METHOD FOR AMPLIFYING IMMUNOSIGNALS
    Publication number: 20200377926
    Abstract: The invention provides an antibody-based bioanalytical method, specifically a hybridization Chain Reaction-based Method for Amplifying Immunosignals named immunosignal HCR (isHCR), which combines antibody-antigen interactions with hybridization Chain Reaction (HCR) technology for amplifying immunosignals. The invention also provides a kit for performing the above isHCR.
    Type: Application
    Filed: January 26, 2018
    Publication date: December 3, 2020
    Applicant: NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING
    Inventors: Rui Lin, Minmin Luo
  • Entacapone for treatment of obesity
    Patent number: 10682329
    Abstract: Obesity is inhibited by administering to a person in need thereof an effective amount of entacapone ((2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide), or a pharmaceutically-acceptable salt thereof, particularly in conjunction with a second, different anti-obesity medicament. Pharmaceutical compositions comprise entacapone copackaged or coformulated with a second, different anti-obesity medicament.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: June 16, 2020
    Assignee: National Institute of Biological Sciences, Beijing
    Inventors: Niu Huang, Gang Zhi, Jijie Chai, Shiming Peng, Nannan Hou
  • Necrosis inhibitors
    Patent number: 10682319
    Abstract: The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: June 16, 2020
    Assignee: National Institute of Biological Sciences, Beijing
    Inventors: Zhiyuan Zhang, Xiaodong Wang, Xiaoguang Lei, Yaning Su, Sudan He, Hanying Ruan, Liming Sun